The original disclosure in Japanese was released on May 14, 2019 at 15:00 (GMT+8)

Consolidated Financial Statements for the Year Ended March 31, 2019
FY2019 (April 1, 2018 - March 31, 2019) [UNAUDITED]May 14, 2019
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takara-bio.co.jp
Koichi Nakao, President
Shuichiro Matsuzaki, Executive Vice President
Tel. (077) 565-6970
Scheduled date of general shareholders’ meeting:June 21, 2019
Scheduled date of starting delivery of dividends:
June 24, 2019
Scheduled date of annual securities report filing date:June 27, 2019
Supplementary documents of the financial results:
Yes
Financial results information meeting:Yes
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

1. Results for the year ended March 31, 2019 (Apr. 1, 2018 – Mar. 31, 2019)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Net sales
Operating income
Ordinary income
Net income (loss) attributable to owners of theparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
Return on equity
Ordinary income to total assets ratio
Operating income to net sales ratio
Note: Comprehensive income(2) Consolidated financial position

Year ended Mar. 31, 2019
(Millions of yen)(%)
35,841
5,463
5,665
3,657

10.9
53.7
46.7
56.6

30.38
-2,705

Year ended Mar. 31, 2018(%)

(Millions of yen)
32,312
3,555
3,861
2,335

10.0
11.0
7.972.6

19.39
5.8%
8.1%
15.2%
(10.2 %)

2,455

3.8%
5.7%
11.0%
(- %)

As of Mar. 31, 2019
(Millions of yen)

As of Mar. 31, 2018
(Millions of yen)

Year ended Mar. 31, 2019
(Millions of yen)

Year ended Mar. 31, 2018
(Millions of yen)

5,783
(5,576)
(541)
9,464

3,935
(14,755)(1,205)
10,051

Total assets
71,04068,670Net assets
64,095
61,959Equity ratio (%)
90.1
90.1
Net assets per share (in yen)531.57513.66(Reference) Equity
64,00961,852
Note: Partial revision of accounting standard related to tax effect accounting (Article 28 on corporate accounting standard,February 16, 2018) has been applied from the beginning of the year ended March 31, 2019. Accordingly, financial position
for the year ended March 31, 2018 indicates the numerical value after retroactive adjustment due to this revision.
(3) Consolidated cash flow
Cash flow from operating activities
Cash flow from investing activities
Cash flow from financing activities
Cash and cash equivalents, end year

The original disclosure in Japanese was released on May 14, 2019 at 15:00 (GMT+8)
2. DividendsFirst quarter end
Second quarter end
Third quarter end
Year end
AnnualTotal dividend (Millions of yen)
Payout ratio (%)
Dividend on equity (%)

Annual dividends per share in yen
Year ended Mar. 31,
Year ending Mar. 31,
20192020 (Forecast)
0.00
0.00
0.00
4.50
7.00
8.00
4.50
7.00
8.00
541
842
23.2
23.0
22.7
0.9
1.3
-Year ended Mar. 31,
2018

3. Forecast for the year ending March 31, 2020 (Apr. 1, 2019 – Mar. 31, 2020)(Percentages indicated changes from the same period of the previous fiscal year.)Net sales
Operating incomeOrdinary income
Net income attributable toowners of the parent
Net income per share (in yen)※Six months ending Sep. 30, 2019
(Millions of yen)(%)
17,1292,917
3,001
1,950(1.4)
11.2
12.4
13.3

16.20

Year ending Mar. 31, 2020

(Millions of yen)
36,000
6,200
6,450
4,250

(%)
0.4
13.5
13.9
16.2

35.29

Others(1) Changes in subsidiaries during the period(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: - (Name)
Excluded: - (Name)(2) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： No
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(3) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of March 31, 2019
120,415,600
As of March 31, 2018
2) Number of treasury stocks at year end
As of March 31, 2019
As of March 31, 2018
3) Average number of outstanding shares
120,415,600
As of March 31, 2019
120,415,600
As of March 31, 2018

※ These financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due
to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Overview of FinancialResults (4) Future Outlook, on page 3 of the attached document.
The Company will hold a briefing for institutional investors and analysts on May 16, 2019. The material handed out at thisbriefing and a review of questions and answers will be posted on our website.
(Change in calendar indication)
Calendar indication has been changed from Japanese style to western style since Consolidated Financial Statements for the firstquarter ended June 30, 2018.